A review of the genotoxicity of marketed pharmaceuticals.
about
Genotoxicity of Anesthetics Evaluated In Vivo (Animals)Prediction of the Carcinogenic Potential of Human Pharmaceuticals Using Repeated Dose Toxicity Data and Their Pharmacological Properties.21-Benzylidene digoxin: a proapoptotic cardenolide of cancer cells that up-regulates Na,K-ATPase and epithelial tight junctionsLook back in anger - what clinical studies tell us about preclinical workIn vitro genotoxicity of rocuronium bromide in human peripheral lymphocytesMoving forward in human cancer risk assessment.Usefulness of monitoring γ-H2AX and cell cycle arrest in HepG2 cells for estimating genotoxicity using a high-content analysis system.Successful drug development despite adverse preclinical findings part 2: examples.The efficacy of 2-nitrovinylfuran derivatives against Leishmania in vitro and in vivoGene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity.Antibiotic use and risk of non-Hodgkin's lymphoma: a population-based case-control study.In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results.Assessment of Potential In vitro Genotoxic and Cytotoxic Effects of Bupropion Hydrochloride (Wellbutrin) in Human Peripheral Lymphocytes and Human Cortical Neuron.Commentary: regulatory toxicology and the critical path: predicting long-term outcomes from short-term studies.Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms.Genomic approaches for investigating mechanisms of genotoxicity.New and emerging technologies for genetic toxicity testing.How accurate is in vitro prediction of carcinogenicity?Genotoxicity and carcinogenicity studies of antihistamines.Genotoxicity and carcinogenicity studies of bronchodilators and antiasthma drugs.Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.Assessing the potential of pharmaceuticals and their transformation products to cause mutagenic effects: Implications for gene expression profiling.Drug use among men with unfulfilled wish to father children: a retrospective analysis and discussion of specific drug classes.Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties.Evaluation of four human cell lines with distinct biotransformation properties for genotoxic screening.International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Evaluation of the GADD45α-GFP GreenScreen HC assay for rapid and reliable in vitro early genotoxicity screening.Metabolic response to low-level toxicant exposure in a novel renal tubule epithelial cell system.Potentiation of the mutagenicity and recombinagenicity of bleomycin in yeast by unconventional intercalating agents.Lovastatin enhances the genotoxicity of doxorubicin in Chinese hamster V79 cells via noncovalent DNA binding.Mutagenic Potential ofBos taurus Papillomavirus Type 1 E6 Recombinant Protein: First Description.Genotoxicity evaluation of asymmetric lipid polymer hybrid nanoparticles of doxycycline hydrochloride following intravenous administration.Genotoxicity assessment of a pharmaceutical effluent using four bioassaysAn evaluation of the genotoxic and cytotoxic effects of the anti-obesity drugs sibutramine and fenproporex.Genotoxic effects in fish induced by pharmacological agents present in the sewage of some Italian water-treatment plants.A Novel Strategy to Predict Carcinogenicity of Antiparasitics Based on a Combination of DNA Lesions and Bacterial Mutagenicity Tests.Effects of acute and chronic administration of fenproporex on DNA damage parameters in young and adult rats.Chromosome instability in T-cells cultured in the presence of pancuronium or fentanyl.Exposure to lambda-cyhalothrin, a synthetic pyrethroid, increases reactive oxygen species production and induces genotoxicity in rat peripheral blood.
P2860
Q26801059-33C48D0C-46F7-4B31-B494-A977B11BCF7AQ27690887-2E0020F9-CA79-416A-BF0B-99541FEFE580Q28395505-BF249A79-408F-4AA3-A722-02E432B53DFBQ28677000-57F25CA3-D04C-4094-A522-7E4EF9331C5FQ34836773-0853EDD6-ADA7-446D-AEE8-B23E5ADAC76BQ35044706-E158437A-0C96-401A-936C-073FFE4E99C8Q35198605-065DE130-C057-4E71-9F74-278C2D4573DEQ35603965-49A4D646-15FD-4FCC-8102-7BAA9538412DQ35810652-487DB489-B71F-4E47-932A-57E89AAF5665Q36186960-C1484DEC-2653-477E-BCE6-BF9E8599549EQ36608726-8B38A9C8-85F8-4B47-989C-8FDF3B6F3788Q36763477-77EB057C-0215-44FC-A686-8EEA42E47477Q36984519-FC8B4951-4127-42AE-BAED-2D212D61C88BQ37251498-DF974923-BFB8-4930-9EE3-C270F69FAC70Q37324752-54FE8090-E501-419B-90D5-D071970B3AC4Q37658716-5A40F7F4-6356-4EE3-9257-F8BC11EE563CQ37782591-1D08BB07-FB7F-490E-8E87-0F2EE80B6E7CQ37811040-3C4686AE-BE33-40AC-AF5B-FBA4391974F3Q37843844-FC462C19-ACD1-4EBE-9480-D8A0A2AB6860Q38078538-39B55EBE-AE84-4AAB-97DE-5C2DD3A47746Q38306555-68F91BEB-B59D-4CB4-B98D-6C0FCBF5EF76Q38737969-8A713923-BC40-4082-ADC6-23F603A2CAADQ38757168-99A5DC00-46BA-41E4-8A08-6DDE944A90DEQ38818082-83B38FDA-6962-4AF1-B666-1A30BB484358Q38846241-141760A0-FC63-4676-9C23-2CABB63C8685Q38904138-6F2151F6-FDE4-49CD-B52B-675574A30B7AQ38954348-FB040137-4877-4888-8DC2-1DC5BA7CCC27Q39313041-275C6909-1C6A-432A-BB65-622990D3458BQ39628420-85B4F3B3-B4BA-43E4-B55D-786029418AA1Q39656167-60F67552-7A27-4451-B2AB-D68E23749AFDQ39839926-BA1CB4CC-835D-4AB2-8501-9143BB521FF9Q40827238-FFC225B4-5F79-47F4-99D2-9587944A8A72Q41195486-E07999F1-3055-4919-B49C-49A5C7D6E860Q42130514-CB18D199-923A-43CE-9D1A-655BEDDF65B1Q43201843-3BD7FA51-E478-4803-AF6F-83ABE1A780ECQ43317906-DCA44641-BAA9-403A-B4BC-B49F31F12C5EQ44292362-4CEBA90E-69E7-4093-9795-0FBE73A69D6CQ44739272-97AB3B67-D9D6-4E2C-99D7-0E172E13A0BDQ45021445-04201CBF-2AA7-45A6-BD2E-DE15BF75F0E1Q45804929-3265FD71-BBF0-4F99-920C-74CEE45CE175
P2860
A review of the genotoxicity of marketed pharmaceuticals.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A review of the genotoxicity of marketed pharmaceuticals.
@ast
A review of the genotoxicity of marketed pharmaceuticals.
@en
A review of the genotoxicity of marketed pharmaceuticals.
@nl
type
label
A review of the genotoxicity of marketed pharmaceuticals.
@ast
A review of the genotoxicity of marketed pharmaceuticals.
@en
A review of the genotoxicity of marketed pharmaceuticals.
@nl
prefLabel
A review of the genotoxicity of marketed pharmaceuticals.
@ast
A review of the genotoxicity of marketed pharmaceuticals.
@en
A review of the genotoxicity of marketed pharmaceuticals.
@nl
P1433
P1476
A review of the genotoxicity of marketed pharmaceuticals.
@en
P2093
P304
P356
10.1016/S1383-5742(01)00055-2
P407
P577
2001-05-01T00:00:00Z